Safety alerts
28 safety alerts appeared in China during Week 16, 2026. Safety concentration usually matters to quality, vigilance, and post-market surveillance teams because it can reveal emerging field risks.
China medical device regulatory intelligence, Week 16, 2026.
Signals from 2026-04-13 to 2026-04-19, covering safety alerts, regulatory changes, device registrations, market movement, and source activity for China.
Signals
40
Sources
5
Index status
Indexable
EXECUTIVE SUMMARY
China generated 40 qualifying medical device signals during Week 16, 2026. Safety alerts led the week with 28 signals, while FDA Device Enforcement was the most active source. AbbVie will pay $30M upfront for two non-opioid pain treatment candidates from Haisco, totaling $745M deal. Kailera raised $625M in a major IPO to fund medicines licensed from Hengrui Pharma.
Key observations
Safety alerts accounted for 28 of 40 qualifying signals, making it the main review lane for the week.
Competitor launches formed the second-largest cluster, which is useful context for teams separating safety work from regulatory and market monitoring.
FDA Device Enforcement contributed 28 signals, so source-level follow-up should start there.
Scan appeared repeatedly in the highlighted signals, which may warrant closer product, manufacturer, or competitor tracking.
Category interpretation
Competitor launches
8 competitor launches appeared in China during Week 16, 2026. Competitor-linked activity is most useful when paired with product codes, indication context, and adjacent safety signals.
Competitor moves
3 competitor moves appeared in China during Week 16, 2026. Competitor-linked activity is most useful when paired with product codes, indication context, and adjacent safety signals.
Market signals
1 market signals appeared in China during Week 16, 2026. Market signals help connect regulatory monitoring with launch planning, reimbursement, and commercial strategy.
Recommended monitoring focus
- Review NMPA safety and recall activity for product categories that overlap your portfolio.
- Review competitor-linked signals for launch timing, market access movement, and product category momentum.
- Use market trend signals to brief commercial, strategy, and market access teams alongside regulatory stakeholders.
Source-backed signal evidence
These source-linked items support the weekly analysis above. They are included for verification and follow-up, not as a raw feed export.
Fierce Biotech·Competitor moves·
AbbVie inks $745M deal with Chinese biotech Haisco for two acute pain assets
AbbVie will pay $30M upfront for two non-opioid pain treatment candidates from Haisco, totaling $745M deal.
SourceBioPharma Dive·Competitor moves·
Kailera nets $625M in one of biotech’s biggest-ever IPOs
Kailera raised $625M in a major IPO to fund medicines licensed from Hengrui Pharma.
SourceEndpoints News·Competitor launches·
Kailera IPO interview: CEO Renaud talks biotech market, China and obesity pipeline
Kailera Therapeutics raised $625 million in a Nasdaq IPO, focusing on obesity treatments and backed by Bain Capital.
SourceEUDAMED EU Device Database·Competitor launches·
EUDAMED: Scan Body by Tianjin Coral Biotechnology Co., Ltd (Class refdata.risk-class.class-i)
Tianjin Coral Biotechnology's Scan Body is registered as a Class I medical device with UDI-DI 06979969951972.
SourceEUDAMED EU Device Database·Competitor launches·
EUDAMED: Scan Body by Tianjin Coral Biotechnology Co., Ltd (Class refdata.risk-class.class-i)
Tianjin Coral Biotechnology's Scan Body is registered as a Class I medical device with UDI-DI 06979969951989.
SourceEUDAMED EU Device Database·Competitor launches·
EUDAMED: Scan Body by Tianjin Coral Biotechnology Co., Ltd (Class refdata.risk-class.class-i)
Tianjin Coral Biotechnology's Scan Body is classified as a Class I medical device with UDI-DI 06979969951996.
SourceEUDAMED EU Device Database·Competitor launches·
EUDAMED: Scan Body by Tianjin Coral Biotechnology Co., Ltd (Class refdata.risk-class.class-i)
Tianjin Coral Biotechnology's Scan Body is registered as a Class I medical device with UDI-DI 06979969951965.
SourceEUDAMED EU Device Database·Competitor launches·
EUDAMED: Scan Body by Tianjin Coral Biotechnology Co., Ltd (Class refdata.risk-class.class-i)
Tianjin Coral Biotechnology's Scan Body is registered as a Class I medical device with UDI-DI 06979969952023.
SourceEUDAMED EU Device Database·Competitor launches·
EUDAMED: Scan Body by Tianjin Coral Biotechnology Co., Ltd (Class refdata.risk-class.class-i)
Tianjin Coral Biotechnology's Scan Body is registered as a Class I medical device with UDI-DI 06979969952016.
SourceFDA Device Enforcement·Safety alerts·
Enforcement Class II: eTRAX Needle Sensor - 12G (for Aurora Trackers), Part Number 667-156 (Civco Medical Instruments Co. Inc.)
Civco Medical recalled the eTRAX Needle Sensor due to potential misidentification of needle tip position.
SourceEUDAMED EU Device Database·Competitor launches·
EUDAMED: Scan Body by Tianjin Coral Biotechnology Co., Ltd (Class refdata.risk-class.class-i)
Tianjin Coral Biotechnology's Scan Body is registered as a Class I medical device with UDI-DI 06979969952009.
SourceFDA Device Enforcement·Safety alerts·
Enforcement Class II: ALLURA Xper FD20 OR Table; System Code: (1) 722015, (2)722023, (3)722035; (PHILIPS MEDICAL SYSTEMS NEDERLAND B.V.)
Philips recalls ALLURA Xper FD20 OR Table due to intermittent X-ray imaging issues with the foot switch.
SourceSafety alerts
FDA Device Enforcement·Safety alerts·
Enforcement Class II: eTRAX Needle Sensor - 12G (for Aurora Trackers), Part Number 667-156 (Civco Medical Instruments Co. Inc.)
Civco Medical recalled the eTRAX Needle Sensor due to potential misidentification of needle tip position.
SourceFDA Device Enforcement·Safety alerts·
Enforcement Class II: ALLURA Xper FD20 OR Table; System Code: (1) 722015, (2)722023, (3)722035; (PHILIPS MEDICAL SYSTEMS NEDERLAND B.V.)
Philips recalls ALLURA Xper FD20 OR Table due to intermittent X-ray imaging issues with the foot switch.
SourceFDA Device Enforcement·Safety alerts·
Enforcement Class II: Paradigm Insulin Pump (MMT-712, MMT-715) (Medtronic MiniMed, Inc.)
Medtronic MiniMed's Paradigm Insulin Pumps are recalled due to risks of insulin over- and under-delivery affecting patient safety.
SourceFDA Device Enforcement·Safety alerts·
Enforcement Class II: Azurion 5 M12; System Code: (1)722227, (2)722231; (PHILIPS MEDICAL SYSTEMS NEDERLAND B.V.)
Philips recalled Azurion 5 M12 due to intermittent X-ray imaging issues with the wired foot switch.
SourceFDA Device Enforcement·Safety alerts·
Enforcement Class II: Atellica CH Enzymatic Hemoglobin A1c (A1c_E); Siemens Material Number (SMN): 11097536; (Siemens Healthcare Diagnostics, Inc.)
Siemens recalls Atellica CH A1c_E due to potential negative bias affecting diabetes diagnosis.
SourceFDA Device Enforcement·Safety alerts·
Enforcement Class II: eTRAX Needle System Starter Kit 14G (for Aurora Trackers), Part Number 667-150 (Civco Medical Instruments Co. Inc.)
Civco Medical recalled the eTRAX Needle System Starter Kit due to potential sensor misidentification.
SourceFDA Device Enforcement·Safety alerts·
Enforcement Class II: eTRAX Needle Sensor - 14G(for Aurora Trackers), Part Number 667-157 (Civco Medical Instruments Co. Inc.)
Civco Medical recalled eTRAX Needle Sensor 14G due to potential misidentification of needle tip position.
SourceFDA Device Enforcement·Safety alerts·
Enforcement Class II: MiniMed 620G Insulin Pump (MMT-1750) (Medtronic MiniMed, Inc.)
Medtronic's MiniMed 620G insulin pump recalled due to risks of insulin over- and under-delivery affecting patient safety.
SourceCompetitor launches
Endpoints News·Competitor launches·
Kailera IPO interview: CEO Renaud talks biotech market, China and obesity pipeline
Kailera Therapeutics raised $625 million in a Nasdaq IPO, focusing on obesity treatments and backed by Bain Capital.
SourceEUDAMED EU Device Database·Competitor launches·
EUDAMED: Scan Body by Tianjin Coral Biotechnology Co., Ltd (Class refdata.risk-class.class-i)
Tianjin Coral Biotechnology's Scan Body is registered as a Class I medical device with UDI-DI 06979969951972.
SourceEUDAMED EU Device Database·Competitor launches·
EUDAMED: Scan Body by Tianjin Coral Biotechnology Co., Ltd (Class refdata.risk-class.class-i)
Tianjin Coral Biotechnology's Scan Body is registered as a Class I medical device with UDI-DI 06979969951989.
SourceEUDAMED EU Device Database·Competitor launches·
EUDAMED: Scan Body by Tianjin Coral Biotechnology Co., Ltd (Class refdata.risk-class.class-i)
Tianjin Coral Biotechnology's Scan Body is classified as a Class I medical device with UDI-DI 06979969951996.
SourceEUDAMED EU Device Database·Competitor launches·
EUDAMED: Scan Body by Tianjin Coral Biotechnology Co., Ltd (Class refdata.risk-class.class-i)
Tianjin Coral Biotechnology's Scan Body is registered as a Class I medical device with UDI-DI 06979969951965.
SourceEUDAMED EU Device Database·Competitor launches·
EUDAMED: Scan Body by Tianjin Coral Biotechnology Co., Ltd (Class refdata.risk-class.class-i)
Tianjin Coral Biotechnology's Scan Body is registered as a Class I medical device with UDI-DI 06979969952023.
SourceEUDAMED EU Device Database·Competitor launches·
EUDAMED: Scan Body by Tianjin Coral Biotechnology Co., Ltd (Class refdata.risk-class.class-i)
Tianjin Coral Biotechnology's Scan Body is registered as a Class I medical device with UDI-DI 06979969952016.
SourceEUDAMED EU Device Database·Competitor launches·
EUDAMED: Scan Body by Tianjin Coral Biotechnology Co., Ltd (Class refdata.risk-class.class-i)
Tianjin Coral Biotechnology's Scan Body is registered as a Class I medical device with UDI-DI 06979969952009.
SourceCompetitor moves
Fierce Biotech·Competitor moves·
AbbVie inks $745M deal with Chinese biotech Haisco for two acute pain assets
AbbVie will pay $30M upfront for two non-opioid pain treatment candidates from Haisco, totaling $745M deal.
SourceBioPharma Dive·Competitor moves·
Kailera nets $625M in one of biotech’s biggest-ever IPOs
Kailera raised $625M in a major IPO to fund medicines licensed from Hengrui Pharma.
SourceFierce Biotech·Competitor moves·
Aligos sells China rights to HBV drug to hepatology player Amoytop in $445M deal
Aligos sold China rights to its HBV treatment to Amoytop for $445M, including a $25M upfront fee.
SourceMarket signals
Fierce Biotech·Market signals·
Roivant’s CEO thinks China is a ‘red herring’
Roivant's CEO views China's biotech rise as a distraction rather than a significant threat.
SourceTrack these signals continuously.
MedFlux monitors regulators and medical device market sources across priority countries so regulatory, quality, and strategy teams can review changes without manually checking agency databases.